Custom service
Lipidation-Based Long-Acting Peptide Design Services
Design lipidation-based long-acting peptide constructs for extended dosing
The service is built around albumin-binder lipid motif design. Depending on the molecule we may move to dosing-interval modeling or potency-preserving modification sites to improve stability, loading or yield, and every batch is released with designed constructs with stability and potency data.
Because Lipidation-Based Long-Acting Peptide Designs projects usually feed a downstream assay or preclinical study, we lock the release specification early — purity, identity and functional readouts are agreed at quotation, not discovered at delivery.
Weekly-dosing peptide concepts
Half-life extension without receptor loss
Depot-mechanism (formulation-led) extension programmes
Programs expecting in-vivo efficacy guarantees from chemistry services
Platform outputs include the design rationale, analytical release of the modified peptide, and in-vitro release/stability datasets that support the chosen dosing concept.
Service Highlights
- Albumin-binder lipid motif design as the default route, with dosing-interval modeling held as a proven fallback
- Potency-preserving modification sites worked into the design where the application requires it
- Half-life strategy selected against the dosing objective (weekly vs monthly), not by fashion
- Analytical confirmation of every intermediate before the final release
- In-vitro release and stability data generated before any in-vivo claim is discussed
- Designed constructs with stability and potency data delivered with a complete conjugation or synthesis certificate
How the work runs
Dosing objective review
Target dosing interval and route define the Lipidation-Based Long-Acting Peptide Design Services design space.
Extension strategy design
albumin-binder lipid motif design and alternatives are modeled against receptor-binding constraints.
Synthesis & modification
Candidate constructs are synthesized with dosing-interval modeling.
In-vitro evaluation
Serum stability, albumin binding and potency are measured across candidates.
Selection & refinement
The lead construct is refined until stability and potency meet the target.
Release
Designed constructs with stability and potency data plus the design dossier is delivered.
Specifications & timeline
- Turnaround
- 6–10 weeks
- Typical scale
- mg – g design batches
- Chemistry options
- albumin-binder lipid motif design; dosing-interval modeling; potency-preserving modification sites
- Deliverable
- Designed constructs with stability and potency data
- QC package
- Design dossier, analytical release, in-vitro release data
- Shipping
- Blue ice with stability handling notes
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.